RHAPSODY, Biomarkers and Novel Clinical Trial design in type 2 diabetes (T2D) and prediabetes

Rachel Adams, Nicole Daly, Elizabeth Robertson, Giuseppe N. Giordano

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskriftPeer review

Sammanfattning

Developing a novel therapeutic product for the treatment of type 2 diabetes (T2D) is a long, resource-intensive process. Novel biomarkers could potentially aid clinical trial design by shortening clinical trials or enabling better prediction of at-risk populations and/or disease progression. Novel clinical trial designs could lead to reduced costs of development and less burden to patients, due to shorter trial duration, and/or less burdensome assessments.

Originalspråkengelska
TidskriftEndocrinology, Diabetes and Metabolism
Volym4
Utgåva2
Tidigt onlinedatum2020 dec. 6
DOI
StatusPublished - 2021

Ämnesklassifikation (UKÄ)

  • Endokrinologi och diabetes

Fingeravtryck

Utforska forskningsämnen för ”RHAPSODY, Biomarkers and Novel Clinical Trial design in type 2 diabetes (T2D) and prediabetes”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här